Roche has secured a new FDA approval for its first companion diagnostic test aimed at identifying breast cancer patients with ...
Just days after the FDA approved AstraZeneca and Daiichi Sankyo's Enhertu for a potentially lucrative new use, the regulatory has now cleared a diagnostic test that could help unlock the drug's ...
HealthDay on MSN6d
FDA Approval Expands Earlier Use of Enhertu for Metastatic Breast CancerThe U.S. Food and Drug Administration has approved Enhertu (trastuzumab deruxtecan) for the treatment of adult patients with ...
AZ and Daiichi are meanwhile continuing to explore new uses for the drug, and recently started dosing patients in DESTINY-Breast11, a phase III trial of Enhertu in neoadjuvant HER2-positive breast ...
The FDA has approved an expanded label for Roche’s PATHWAY anti-HER2/neu (4B5) Rabbit Monoclonal Primary Antibody test, which ...
AstraZeneca on Thursday warned that it could be fined millions of dollars in importation tax fines as Chinese authorities ...
AstraZeneca reports mixed results in the fourth quarter. It gains in pre-market after assuring investors that the business ...
Verywell Health on MSN4d
A New 'Missile' Drug Is Approved To Treat the Most Common Breast Cancer TypeThe FDA approved Datroway to treat metastatic or unresectable HR+/HER2- breast cancer in people who have tried standard chemo ...
Keeping a lid on drug prices is proving costly for ambitions to turn the UK into a life sciences superpower ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback